{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28"],"submitter":["Guisado-Vasco P"],"pubmed_abstract":["Background
The COVID-19 outbreak challenges the Spanish health system since March 2020. Some available therapies (antimalarials, antivirals, biological agents) were grounded on clinical case observations or basic science data. The aim of this study is to describe the characteristics and impact of different therapies on clinical outcomes in a cohort of severe COVID-19 patients.Methods
In this retrospective, single-center, observational study, we collected sequential data on adult patients admitted to Hospital Universitario Quironsalud Madrid. Eligible patients should have a microbiological (positive test on RT-PCR assay from a nasal swab) or an epidemiological diagnosis of severe COVID-19. Demographic, baseline comorbidities, laboratory data, clinical outcomes, and treatment"],"journal":["EClinicalMedicine"],"pagination":["100591"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7557296"],"repository":["biostudies-literature"],"pubmed_title":["Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)."],"pmcid":["PMC7557296"],"pubmed_authors":["Malo-Benages EJ","Andreu-Vazquez C","Carnevali-Ruiz D","Comeche-Casanova L","Barrena-Puertas R","Marti-Ballesteros EM","Recio-Rodriguez M","Gonzalez-Cortijo L","Monforte-Gomez MJ","Diez-Munar R","Roda-Santacruz A","Carralon-Gonzalez MM","Sotres-Fernandez G","Rodriguez-Lopez M","Thuissard-Vasallo IJ","Almagro-Casado E","Luque-Pinilla JM","Merino-Lanza E","Remirez-de-Esparza-Otero M","Valderas-Ortega S","La Coma-Lanuza FJ","Sanchez-Manzano MD","Guisado-Vasco P","Maria-Tome JME","Correyero-Plaza M"],"additional_accession":[]},"is_claimable":false,"name":"Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).","description":"Background
The COVID-19 outbreak challenges the Spanish health system since March 2020. Some available therapies (antimalarials, antivirals, biological agents) were grounded on clinical case observations or basic science data. The aim of this study is to describe the characteristics and impact of different therapies on clinical outcomes in a cohort of severe COVID-19 patients.Methods
In this retrospective, single-center, observational study, we collected sequential data on adult patients admitted to Hospital Universitario Quironsalud Madrid. Eligible patients should have a microbiological (positive test on RT-PCR assay from a nasal swab) or an epidemiological diagnosis of severe COVID-19. Demographic, baseline comorbidities, laboratory data, clinical outcomes, and treatment","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2026-06-03T22:18:45.268Z","creation":"2020-10-29T14:50:27Z"},"accession":"S-EPMC7557296","cross_references":{"pubmed":["33078138"],"doi":["10.1016/j.eclinm.2020.100591"]}}